Research progress on Kunxian Capsule in the treatment of proteinuria

Read full text Summarise with VIRAT
Authors: Li Shi-yan, Wu Yan-ping, Zheng Han-yan, Wang Xiao-qin
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Proteinuria is a major driver of renal disease progression and a key therapeutic target. Kunxian Capsules (Kunxian; a third‑generation Tripterygium‑based compound) combine four herbal ingredients, including Tripterygium hypoglaucum and Epimedium, to enhance therapeutic effect while mitigating toxicity. This integrative Chinese-Western formulation has been increasingly applied in the management of proteinuric kidney diseases, notably IgA nephropathy, diabetic kidney disease, lupus nephritis, membranous nephropathy, and Henoch-Schönlein purpura⁃associated nephritis. Here, we review current evidence on Kunxian's putative pharmacological actions, summarize clinical efficacy and safety findings, and discuss practical considerations for use. We emphasize the need for dynamic patient monitoring and individualized dosing to optimize benefit and limit adverse effects to provide a reference for rational clinical use.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Traditional Chinese Medicine Clinical Research Natural Compounds in Disease Treatment

Publication details

Journal / source
DOAJ (DOAJ: Directory of Open Access Journals)
Publication date
1 March 2026
Language
ZH